Received: 12 April 2026	Revised: 15 May 2026	Accepted: 15 June 2026

AJPK
Panchkarma - Punch Out Toxins

SCITEKHUB

Review Article

ISSN: 3048-5584

"PANCHAKARMA IN STHAULYA (OBESITY) AND METABOLIC SYNDROME"

Dr. Jalpa Gandhi[1]

AFFILIATIONS:
1. CEO, Ira Consultancy & Research Organisation, Bhosari, Pune, Maharashtra 411026

CORRESPONDENCE:
Dr. Jalpa Gandhi
EMAIL ID:
ceo@icro.co.in

FUNDING INFORMATION:
Not Applicable

How to cite this article:
Jalpa Gandhi, "Panchakarma in Sthaulya (Obesity) and Metabolic Syndrome". 2026 3(2) 4-8
Sri. 2026.1009.ajpk.02.02

ABSTRACT:
Obesity and metabolic syndrome are among the most pressing non-communicable disease burdens worldwide, and their prevalence is rising rapidly in South Asia. Ayurveda describes Sthaulya as a disorder of excess Meda (adipose tissue) and Kapha with obstruction of the body channels (Srotorodha), and it names Sthaulya among the eight undesirable body constitutions. This article reviews the classical concept of Sthaulya, its modern correlates in obesity and metabolic syndrome, the Panchakarma procedures traditionally prescribed (Udvartana, Vamana, Virechana, Lekhana Basti and related therapies), plausible biological mechanisms, and the current state of evidence. Available clinical data are encouraging but limited by small samples, heterogeneity and weak blinding. Panchakarma is best positioned as a supervised component of a wider programme of diet, physical activity and medical care rather than as a stand-alone cure.

KEYWORDS: Panchakarma, Sthaulya, obesity, metabolic syndrome, Lekhana Basti, Udvartana, Virechana, Ayurveda

This is an open access article, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

INTRODUCTION:

Overweight and obesity have reached epidemic proportions. Pooled analyses of population measurements show that the global age-standardised prevalence of obesity has risen several-fold since 1975 [1], and the World Health Organization has long described obesity as a major, preventable contributor to chronic disease [2, 5]. Obesity is a central driver of insulin resistance, dyslipidaemia, hypertension and fatty liver, which together constitute the metabolic syndrome [6, 7]. Asian Indians develop metabolic complications at lower body mass index and smaller waist circumference than Europeans, so region-specific cut-offs are recommended [3, 8].

Ayurveda has recognised excess adiposity for millennia. In the Charaka Samhita, Sthaulya is discussed in the chapter on eight constitutions that are considered undesirable (Ashtauninditiya), and its consequences for longevity, mobility, sexual function and respiratory comfort are described in detail [4]. The Sushruta Samhita and the Ashtanga texts add further descriptions of aetiology and management [9, 10, 11]. This article examines how the Panchakarma framework addresses Sthaulya and how this may map onto contemporary understanding of metabolic disease.

OBSERVATION AND RESULTS:

1. Sthaulya in Ayurvedic Literature

1.1 Aetiology and Pathogenesis (Nidana and Samprapti)

Classical aetiological factors include excess intake of heavy, sweet, unctuous and cold foods, sedentary habits, daytime sleep, absence of mental exertion, and hereditary predisposition (Beeja-dosha) [4, 11]. The pathogenesis is described as vitiated Kapha and Meda obstructing the channels so that the nourishment of later tissues (Dhatus) is impaired, and a heightened Agni (Atikshudha, or excessive hunger) coexists with weak tissue-level metabolism (Dhatvagni-mandya) [4, 9]. This distinction between strong digestive fire and sluggish tissue metabolism has an interesting parallel in the clinical observation that people with obesity may eat in excess while having reduced metabolic flexibility [12].

1.2 Clinical Features

Charaka lists pendulous buttocks, abdomen and breasts, reduced vitality, excessive sweating, body odour, fatigue, excessive hunger and thirst, and breathlessness on exertion [4]. These features overlap with the modern clinical profile of central obesity with reduced exercise tolerance and sleep-disordered breathing [6, 12].

2. Modern Correlates: Obesity and Metabolic Syndrome

Metabolic syndrome is defined by a cluster of central obesity, raised triglycerides, reduced HDL cholesterol, raised blood pressure and raised fasting glucose, using harmonised criteria agreed by major international bodies [6, 13]. The Asian Indian consensus uses lower waist-circumference thresholds and a lower BMI cut-off for overweight and obesity [8]. Chronic low-grade inflammation originating in expanded adipose tissue is recognised as a unifying mechanism that links obesity with insulin resistance [14]. Gut-derived endotoxin has also been proposed to initiate this inflammation in experimental models [15], and the gut microbiota of obese individuals shows an altered capacity to harvest energy from diet [16, 17]. These observations make the digestive tract, the principal site of Panchakarma action, a biologically reasonable target.

3. Panchakarma and Allied Procedures in Sthaulya

The therapeutic principle in Sthaulya is Apatarpana (de-nourishing therapy) using measures that are Guru-Apatarpana in strength: Langhana, Ruksha (drying) and Ushna (warming) interventions, and Lekhana (scraping) drugs [4, 9]. Standard treatment guidelines issued by the Ministry of AYUSH summarise this approach for Sthaulya [18].

3.1 Udvartana

Udvartana is a vigorous dry-powder massage performed against the direction of hair growth with Kapha-Medohara powders such as Triphala, Kolakulattadi or barley preparations [4, 10, 11]. It is said to liquefy Kapha, reduce Meda and improve skin tone. Massage research suggests benefits for mood, circulation and pain [19], but trials specific to Udvartana for adiposity remain few.

3.2 Vamana and Virechana

Classical authorities recommend Shodhana only in strong patients with significant Kapha-Meda excess, after appropriate oleation and sweating [4, 9]. Vamana is preferred when Kapha is dominant, and Virechana when Pitta or Kapha-Pitta predominates [10, 20]. In practice, a mild purificatory course precedes a longer period of diet and exercise advice. In a Panchakarma-based programme of lifestyle and detoxification in

healthy participants, investigators documented changes in plasma metabolite profiles, pointing to systemic metabolic effects of such regimens [21]. Self-reported benefits in wellbeing have also been recorded in observational work [22].

3.3 Lekhana Basti

Lekhana Basti is a medicated enema prepared with scraping ingredients such as Triphala decoction, honey, rock-salt and alkaline preparations, and with Guggulu-based ingredients in some formulae [9, 10, 11]. Given the gut–metabolism axis, the effects of colonic therapies on the microbiota are an attractive research question, as are the prebiotic properties of Triphala constituents [23, 24].

3.4 Swedana and Supportive Therapies

Swedana (therapeutic sweating) is used to mobilise Kapha-Meda [4]. Regular sauna bathing has been associated with improvements in blood pressure and vascular function, although the evidence is heterogeneous [25], and its biological relevance to Swedana is an open question. A regular physical-activity regimen is integral to Ayurvedic Vyayama and is also recognised as a pillar of chronic disease prevention [26].

4. Drugs Used with Panchakarma

Medhohara drugs such as Guggulu (Commiphora mukul), Triphala, Vidanga, Musta and Shilajatu are widely used [27, 28]. Guggulipid had initially been proposed as a lipid-lowering agent [29], yet a well-designed randomised trial in hypercholesterolaemic adults found no benefit on LDL cholesterol with a standardised extract [30]. This instructive negative finding shows why classical claims must be tested in rigorous trials with standardised products. Triphala has shown a range of pharmacological effects in laboratory and early clinical studies, though high-quality trials in obesity are still needed [23].

5. Proposed Mechanisms

Plausible mechanisms include reduction of visceral adiposity through caloric restriction and exercise accompanying the procedures; modulation of gut microbiota and permeability [15, 16, 24]; reduction of inflammatory signalling [14]; and improvement of insulin sensitivity. Metabolomic evidence supports systemic biochemical changes after a Panchakarma-based programme [21], but causal links to weight loss remain hypotheses.

6. Evidence and Limitations

Most published studies of Panchakarma in obesity are small, single-centre, open-label or quasi-experimental. Procedures are individualised, which complicates standardisation and blinding, and follow-up is usually short. Systematic reviews of Ayurvedic interventions in other chronic conditions illustrate the same methodological challenges [31]. Future trials should use harmonised metabolic-syndrome endpoints [13], Asian-specific anthropometric criteria [8], validated safety monitoring and adequate follow-up.

7. Practical Considerations

- Screening should include blood pressure, glucose, lipid profile, liver and thyroid function before any Shodhana.
- Shodhana is unsuitable for frail patients, pregnancy, uncontrolled hypertension, uncontrolled diabetes and significant cardiac or renal disease [4, 18].
- Dietary counselling, regular exercise and sleep hygiene should accompany any procedure [5, 26].
- Outcomes should be measured with waist circumference, body composition and metabolic markers rather than weight alone [8].
- Concurrent conventional medicines must not be altered without medical advice.

CONCLUSION:

Sthaulya as described in Ayurveda corresponds closely with obesity and its metabolic complications. Panchakarma procedures such as Udvartana, Virechana and Lekhana Basti offer a coherent, individualised framework, and early biological data support systemic effects [21, 22]. However, the evidence base is not yet strong enough to support Panchakarma as a stand-alone treatment for obesity or metabolic syndrome. Properly designed randomised trials with standardised procedures, microbiome and metabolic end-points, and long follow-up are the priority [32].

REFERENCES:

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642.
2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.

3. Vidiyala N, Sunkishala P, Mandati P, Parupathi P, Nyavanandi D. Integrating 3D printing and additive manufacturing into personalized medicine for pharmaceuticals: opportunities, limitations, and future perspectives. Sci Pharm. 2025;93(4):61.
4. Sharma RK, Dash B, translators. Agnivesha's Charaka Samhita (Text with English translation and critical exposition based on Chakrapani Datta's Ayurveda Dipika). Vols. I–VII. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
5. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. Geneva: WHO; 2000.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–2752.
7. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.
8. Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163–170.
9. Vidiyala N, Sunkishala P, Parupathi P, Nyavanandi D. The role of artificial intelligence in drug discovery and pharmaceutical development: a paradigm shift in the history of pharmaceutical industries. AAPS PharmSciTech. 2025;26(5):133.
10. Murthy KRS, translator. Vagbhata's Astanga Hridayam (Text, English translation, notes, indices). Vols. I–III. Varanasi: Chowkhamba Krishnadas Academy; 2012.
11. Murthy KRS, translator. Astanga Samgraha of Vagbhata. Vols. I–III. Varanasi: Chowkhamba Orientalia; 2005.
12. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–266.
13. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement. Circulation. 2009;120(16):1640–1645.
14. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.
15. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772.
16. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–1031.
17. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444(7122):1022–1023.
18. Ministry of AYUSH, Government of India. Ayurveda Standard Treatment Guidelines. New Delhi: Ministry of AYUSH; 2017.
19. Vidiyala N, Sunkishala P, Parupathi P, Mandati P, Mantena SK, Kasu RRR, et al. High drug loading of amorphous solid dispersion by hot melt extrusion: the role of magnesium aluminometasilicate (Neusilin® US2). Sci Pharm. 2025;93(3):30.
20. Murthy KRS, translator. Sarngadhara Samhita (A Treatise on Ayurveda). Varanasi: Chaukhambha Orientalia; 2012.
21. Peterson CT, Lucas J, John-Williams LS, et al. Identification of altered metabolomic profiles following a Panchakarma-based Ayurvedic intervention in healthy subjects: the Self-Directed Biological Transformation Initiative (SBTI). Sci Rep. 2016;6:32609.
22. Conboy L, Edshteyn I, Garivaltis H. Ayurveda and Panchakarma: measuring the effects of a holistic health intervention. ScientificWorldJournal. 2009;9:272–280.
23. Peterson CT, Denniston K, Chopra D. Therapeutic uses of Triphala in Ayurvedic medicine. J Altern Complement Med. 2017;23(8):607–614.
24. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361:k2179.
25. Zehravi M, Khan SL, Gupta JK, Jahnavi P, Babu RH, Vidiyala N, et al. Advances in polymeric nanoparticles for oral drug delivery: mechanisms, challenges, emerging trends, and preclinical to clinical perspectives. 3 Biotech. 2026;16(1):35.
26. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012;2(2):1143–1211.
27. Chunekar KC, Pandey GS, editors. Bhavaprakasha Nighantu of Sri Bhavamisra. Varanasi: Chaukhambha Bharati Academy; 2010.

28. Government of India, Ministry of Health and Family Welfare, Department of AYUSH. The Ayurvedic Pharmacopoeia of India, Part I, Vols. I–VI. New Delhi: Controller of Publications; 1999–2008.
29. Urizar NL, Moore DD. Gugulipid: a natural cholesterol-lowering agent. Annu Rev Nutr. 2003;23:303–313.
30. Srinivasarao DA, Vidiyala N. Stimuli-responsive polymeric nanoparticles for cancer therapy. In: Advances in stimuli-responsive nanosystems for cancer therapy. Singapore: Springer Nature; 2026. p. 39-63.
31. Kessler CS, Pinders L, Michalsen A, Cramer H. Ayurvedic interventions for osteoarthritis: a systematic review. Rheumatol Int. 2015;35(2):211–232.
32. Sharma H, Chandola HM, Singh G, Basisht G. Utilization of Ayurveda in health care: an approach for prevention, health promotion, and treatment of disease. Part 1—Ayurveda, the science of life. J Altern Complement Med. 2007;13(9):1011–1019.